Home › Companies › NKTX

Nkarta

NKTX Rare disease Lead: Phase 1 1 Biotech Distilled article ↓

Most recent annual filing: 2026-03-25

Pipeline (7 active programs)

NKX019

Cell Target: CD19

Lupus Nephritis Phase 1
Primary Membranous Nephropathy Phase 1
Systemic Sclerosis Phase 1
Idiopathic Inflammatory Myopathy Phase 1
ANCA-Associated Vasculitis Phase 1
Systemic Lupus Erythematosus Phase 1 Columbia University Irving Medical Center
Myasthenia Gravis Phase 1 University of California, Irvine

Technology platforms

CAR NK Platform

Modular NK cell engineering platform utilizing healthy donor-derived NK cells with proprietary technologies for expansion (NKSTIM cells), persistence (mbIL-15), CAR targeting/signaling, CRISPR-Cas9 genome editing, immune evasion, and cryopreservation. Enables off-the-shelf allogeneic CAR NK cell therapies; current focus on autoimmune diseases and prior oncology programs.

Discontinued (2)

NKX019 — undisclosed · deprioritized to direct primary resources to NKX019 for autoimmune diseases; enrollment closed 2023
NKX101 — undisclosed · deprioritized; oncology study closed patient enrollment in 2023

Biotech Distilled coverage (1)

2026-05-26 Nkarta (NKTX) — Scientific Deep Dive for NKX019 and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.